Preferred Stock OfferingsBy Preferred Stock Channel Staff, updated Fri, May 20, 10:11 PM
|This Slide: #222 of 581|
Slide #222. CTI BioPharma Corp. — Preferred Stock Offering
CTI BioPharma Corp. (NASDAQ:CTIC)
Preferred Stock Offering Details:
CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced that it intends to offer and sell, subject to market and other conditions, shares of its Series N-3 Preferred Stock in an underwritten public offering (the "Offering"). Each share of Series N-3 Preferred Stock will have a stated value of $1,000 per share and will be convertible at the option of the holder, at any time after issuance and subject to certain limitations, into shares of common stock.
CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers where there is an unmet medical need. Co. has one commercially approved product, VONJO (pacritinib), which has received approval in the U.S. by the U.S. Food and Drug Administration for the treatment of adult patients with intermediate or primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10^9/L.
Open the CTIC Page at Preferred Stock Channel »
Free CTIC Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Strong Buy (3.75 out of 4)
(ranked higher than approx. 65% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com